237 related articles for article (PubMed ID: 35676822)
1. Integrative metabolomics and transcriptomics analysis reveals novel therapeutic vulnerabilities in lung cancer.
Thaiparambil J; Dong J; Grimm SL; Perera D; Ambati CSR; Putluri V; Robertson MJ; Patel TD; Mistretta B; Gunaratne PH; Kim MP; Yustein JT; Putluri N; Coarfa C; El-Zein R
Cancer Med; 2023 Jan; 12(1):584-596. PubMed ID: 35676822
[TBL] [Abstract][Full Text] [Related]
2. [Identification of differentially expressed genes between lung adenocarcinoma and squamous cell carcinoma using transcriber signature analysis].
Peng S; Li X; Liu Q; Zhang Y; Zou L; Gong X; Wang M; Ma X
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Jun; 39(6):641-649. PubMed ID: 31270041
[TBL] [Abstract][Full Text] [Related]
3. System analysis of
Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
[TBL] [Abstract][Full Text] [Related]
4. Bioinformatic analysis revealing mitotic spindle assembly regulated NDC80 and MAD2L1 as prognostic biomarkers in non-small cell lung cancer development.
Wei R; Wang Z; Zhang Y; Wang B; Shen N; E L; Li X; Shang L; Shang Y; Yan W; Zhang X; Ma W; Wang C
BMC Med Genomics; 2020 Aug; 13(1):112. PubMed ID: 32795325
[TBL] [Abstract][Full Text] [Related]
5. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Li N; Wang J; Zhan X
Front Immunol; 2021; 12():752643. PubMed ID: 34887858
[TBL] [Abstract][Full Text] [Related]
6. Bioinformatics analysis of differentially expressed miRNAs in non-small cell lung cancer.
Yu H; Pang Z; Li G; Gu T
J Clin Lab Anal; 2021 Feb; 35(2):e23588. PubMed ID: 32965722
[TBL] [Abstract][Full Text] [Related]
7. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Li N; Li Y; Zheng P; Zhan X
Front Endocrinol (Lausanne); 2021; 12():755805. PubMed ID: 34745015
[TBL] [Abstract][Full Text] [Related]
8. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.
Yang Y; Wang M; Liu B
J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601
[TBL] [Abstract][Full Text] [Related]
9. Metabolomic, transcriptomic and genetic integrative analysis reveals important roles of adenosine diphosphate in haemostasis and platelet activation in non-small-cell lung cancer.
Hoang LT; Domingo-Sabugo C; Starren ES; Willis-Owen SAG; Morris-Rosendahl DJ; Nicholson AG; Cookson WOCM; Moffatt MF
Mol Oncol; 2019 Nov; 13(11):2406-2421. PubMed ID: 31461552
[TBL] [Abstract][Full Text] [Related]
10. GPC3 affects the prognosis of lung adenocarcinoma and lung squamous cell carcinoma.
Ning J; Jiang S; Li X; Wang Y; Deng X; Zhang Z; He L; Wang D; Jiang Y
BMC Pulm Med; 2021 Jun; 21(1):199. PubMed ID: 34112123
[TBL] [Abstract][Full Text] [Related]
11. Network module function enrichment analysis of lung squamous cell carcinoma and lung adenocarcinoma.
Li P; Yuan H; Kuang X; Zhang T; Ma L
Medicine (Baltimore); 2022 Nov; 101(47):e31798. PubMed ID: 36451444
[TBL] [Abstract][Full Text] [Related]
12. Prognostic alternative mRNA splicing signature in non-small cell lung cancer.
Li Y; Sun N; Lu Z; Sun S; Huang J; Chen Z; He J
Cancer Lett; 2017 May; 393():40-51. PubMed ID: 28223168
[TBL] [Abstract][Full Text] [Related]
13. ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma.
Hou G; Lu Z; Bi Y; Deng J; Yang X
Med Oncol; 2022 Feb; 39(5):51. PubMed ID: 35150321
[TBL] [Abstract][Full Text] [Related]
14. Systematic analysis of IGF2BP family members in non-small-cell lung cancer.
Gong L; Liu Q; Jia M; Sun X
Hum Genomics; 2024 Jun; 18(1):63. PubMed ID: 38867248
[TBL] [Abstract][Full Text] [Related]
15. A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.
Yang K; Wu Y
BMC Cancer; 2021 Feb; 21(1):128. PubMed ID: 33549049
[TBL] [Abstract][Full Text] [Related]
16. Transcriptomic analysis of tumor tissues and organoids reveals the crucial genes regulating the proliferation of lung adenocarcinoma.
Ma X; Yang S; Jiang H; Wang Y; Xiang Z
J Transl Med; 2021 Aug; 19(1):368. PubMed ID: 34446056
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.
Gan BL; He RQ; Zhang Y; Wei DM; Hu XH; Chen G
Int J Oncol; 2018 Oct; 53(4):1557-1579. PubMed ID: 30066858
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Profiling of Genomic and Transcriptomic Differences between Risk Groups of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Zengin T; Önal-Süzek T
J Pers Med; 2021 Feb; 11(2):. PubMed ID: 33672117
[TBL] [Abstract][Full Text] [Related]
19. Transcriptomic FHIT
Brisebarre A; Ancel J; Ponchel T; Loeffler E; Germain A; Dalstein V; Dormoy V; Durlach A; Delepine G; Deslée G; Polette M; Nawrocki-Raby B
Front Immunol; 2022; 13():1058531. PubMed ID: 36544755
[TBL] [Abstract][Full Text] [Related]
20. Transcriptome analysis of distinct long non-coding RNA transcriptional fingerprints in lung adenocarcinoma and squamous cell carcinoma.
Wei Y; Zhang X
Tumour Biol; 2016 Oct; ():. PubMed ID: 27797003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
